Business Insider24d
Blueprint Medicines: Promising Pipeline and Financial Strength Justify Buy Rating
including Blueprint Medicines Corporation’s promising pipeline and financial strength. The company’s recent corporate update highlighted significant milestones and potential market ...
Business Insider24d
Blueprint Medicines: Promising Growth with Increased Sales Projections and Innovative Pipeline Supports Buy Rating
Furthermore, Blueprint Medicines’ innovative pipeline, specifically the BLU-808, shows a differentiated clinical development plan that enhances its competitive position in the biotechnology space.
pharmaphorum5y
Ipsen adds Blueprint's FOP rare disease drug to pipeline for $535m
The deal with Blueprint Medicines for BLU-782, an ALK2 inhibitor class drug, builds on Ipsen’s acquisition of the Canadian rare diseases biotech Clementia Pharmaceuticals for up to $1.31 billion ...